EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 417 filers reported holding EXELIXIS INC in Q1 2024. The put-call ratio across all filers is 0.60 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $6,548,095 | -33.7% | 291,415 | -30.0% | 0.02% | -36.7% |
Q1 2024 | $9,881,243 | -50.5% | 416,403 | -50.0% | 0.03% | -6.2% |
Q4 2023 | $19,973,450 | +114.4% | 832,574 | +95.3% | 0.03% | -3.0% |
Q3 2023 | $9,315,900 | -7.0% | 426,357 | -18.7% | 0.03% | 0.0% |
Q2 2023 | $10,020,099 | -0.2% | 524,338 | +1.4% | 0.03% | -5.7% |
Q1 2023 | $10,037,357 | +19.0% | 517,123 | -1.6% | 0.04% | +16.7% |
Q4 2022 | $8,431,474 | -14.3% | 525,653 | -16.3% | 0.03% | +57.9% |
Q3 2022 | $9,844,015 | -1.9% | 627,808 | +30.2% | 0.02% | 0.0% |
Q2 2022 | $10,035,828 | -57.6% | 482,020 | -53.8% | 0.02% | -44.1% |
Q1 2022 | $23,644,450 | +148.0% | 1,043,004 | +100.0% | 0.03% | +41.7% |
Q4 2021 | $9,533,000 | -12.5% | 521,497 | +1.2% | 0.02% | -22.6% |
Q3 2021 | $10,894,000 | -40.3% | 515,362 | -48.6% | 0.03% | +19.2% |
Q2 2021 | $18,258,000 | +30.1% | 1,002,080 | +61.3% | 0.03% | -39.5% |
Q1 2021 | $14,033,000 | +26.4% | 621,236 | +12.3% | 0.04% | +22.9% |
Q4 2020 | $11,103,000 | -32.7% | 553,175 | -18.0% | 0.04% | -41.7% |
Q3 2020 | $16,498,000 | -57.7% | 674,766 | -58.9% | 0.06% | -22.1% |
Q2 2020 | $38,980,000 | +702.7% | 1,641,980 | +719.4% | 0.08% | +266.7% |
Q3 2017 | $4,856,000 | +266.5% | 200,400 | -43.1% | 0.02% | +320.0% |
Q2 2015 | $1,325,000 | +48.4% | 352,296 | +1.3% | 0.01% | +25.0% |
Q1 2015 | $893,000 | +79.7% | 347,617 | +0.7% | 0.00% | +100.0% |
Q4 2014 | $497,000 | -5.5% | 345,111 | +0.5% | 0.00% | 0.0% |
Q3 2014 | $526,000 | -84.6% | 343,514 | -66.0% | 0.00% | -85.7% |
Q2 2014 | $3,421,000 | -7.0% | 1,009,141 | -2.9% | 0.01% | -12.5% |
Q1 2014 | $3,678,000 | -43.3% | 1,039,070 | -1.8% | 0.02% | -44.8% |
Q4 2013 | $6,489,000 | +33.5% | 1,058,563 | +26.8% | 0.03% | +20.8% |
Q3 2013 | $4,859,000 | +48.6% | 834,944 | +16.0% | 0.02% | +41.2% |
Q2 2013 | $3,269,000 | – | 719,940 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 15,001,073 | $320,572,000 | 64.48% |
Sargent Investment Group, LLC | 432,125 | $9,235,000 | 4.22% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 443,534 | $9,483,000 | 3.52% |
Bellevue Group AG | 3,878,800 | $82,890,000 | 1.42% |
CAPITAL MANAGEMENT CORP /VA | 237,855 | $5,083,000 | 1.40% |
Orbimed Advisors | 3,912,900 | $83,619,000 | 1.30% |
Portolan Capital Management | 540,590 | $11,552,000 | 1.24% |
TEALWOOD ASSET MANAGEMENT INC | 139,347 | $2,978,000 | 1.21% |
Signition LP | 84,120 | $1,798,000,000 | 1.18% |
Penn Capital Management Company, LLC | 529,630 | $11,318,000 | 1.12% |